Report cover image

Non-opioid Pain Treatment Market Growth, Size, Trends Analysis - By Drug Class, By Pain, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Mar 03, 2025
Length 220 Pages
SKU # SPER19991549

Description

Non-opioid Pain Treatment Market Introduction and Overview

According to SPER market research, ‘Global Non-opioid Pain Treatment Market Size- By Drug Class, By Pain, By Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Non-opioid Pain Treatment Market is predicted to reach 104.89 billion by 2034 with a CAGR of 7.53%.

Non-opioid pain treatments are pharmacological therapies that alleviate pain without relying on opioids, which can lead to addiction and other negative consequences. This group mostly includes NSAIDs, analgesics, antidepressants, and other pharmaceuticals. Non-opioid analgesics are becoming increasingly popular due to their safety and efficacy in treating both acute and chronic pain.

Restraints:The side effects of non-opioid medications are creating significant barriers to the growth of the non-opioid pain management market. Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), the most popular type of nonopioid painkiller available, has been linked to an increased risk of gastrointestinal, renal, and cardiovascular complications. NSAIDs can induce gastritis, ulcers, and in severe cases, gastrointestinal bleeding.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments coveredBy Drug Class, By Pain, By Route of Administration, By Distribution Channel.

Regions covered:
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Novartis AG, Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd, Sun Pharmaceutical Industries Ltd, GSK plc, Pfizer Inc, Perrigo Company plc, LNK International, Inc, Cipla Inc, Johnson & Johnson Services, Inc, Pacira Pharmaceuticals, Inc, Pierrel. and others.

Non-opioid Pain Treatment Market Segmentation:

By Drug Class:Based on the Drug Class, Global Non-opioid Pain Treatment Market is segmented as; NSAIDs, Acetaminophen, Local Anesthetics, Other Drug Class.

By Pain:Based on the Pain, Global Non-opioid Pain Treatment Market is segmented as; Post-operative Pain, Cancer Pain, Chronic Pain, Other Pain.

By Route of Administration:Based on the Route of Administration, Global Non-opioid Pain Treatment Market is segmented as; Oral, Topical, Injectable, Other Route of Administration.

By Distribution Channel:Based on the Distribution Channel, Global Route of Administration Market is segmented as. Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.



By Region:This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

220 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Non-opioid Pain Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Non-opioid Pain Treatment Market
7. Global Non-opioid Pain Treatment Market, By Drug Class (USD Million) 2021-2034
7.1. NSAIDs
7.1.1. Non Selective NSAIDs
7.1.2. Selective COX-2 Inhibitors
7.2. Acetaminophen
7.3. Local Anesthetics
7.4. Other Drug Class
8. Global Non-opioid Pain Treatment Market, By Pain (USD Million) 2021-2034
8.1. Post-operative Pain
8.2. Cancer Pain
8.3. Chronic Pain
8.4. Other Pain
9. Global Non-opioid Pain Treatment Market, By Route of Administration (USD Million) 2021-2034
9.1. Oral
9.2. Topical
9.3. Injectable
9.4. Other Route of Administration
10. Global Non-opioid Pain Treatment Market, By Distribution Channel (USD Million) 2021-2034
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies
11. Global Non-opioid Pain Treatment Market, (USD Million) 2021-2034
11.1. Global Non-opioid Pain Treatment Market Size and Market Share
12. Global Non-opioid Pain Treatment Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Novartis AG
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Teva Pharmaceutical Industries Limited
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Dr. Reddys Laboratories Ltd
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Sun Pharmaceutical Industries Ltd
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. GSK plc
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Pfizer Inc
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Perrigo Company plc
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. LNK International, Inc
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Cipla Inc
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Johnson & Johnson Services, Inc
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Pacira Pharmaceuticals, Inc
13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments
13.12. Pierrel
13.12.1. Company details
13.12.2. Financial outlook
13.12.3. Product summary
13.12.4. Recent developments
13.13. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us